Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LeonaBio, Inc.LONA · Entity 1487 | Director | June 23, 2026 | June 24, 2026 |
| Vaxcyte, Inc.PCVX · Entity 1164 | Director · CHIEF EXECUTIVE OFFICER | September 08, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LeonaBio, Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.35 · Expires 2036-06-22 | Direct | 28,000 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 28,000 · Balance 28,000 F1: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.
Vaxcyte, Inc.
Report date September 08, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 429,902 |
Reported balance
After 2026-09-08 transaction · row 1
1 source rowRow 1 · 2026-09-08 · Tax withholding · Disposed 17,056 · Balance 429,902 F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. |
| Common StockSEC Table I · non-derivative | IndirectBy Children's Trust | 133,215 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 133,215 F2: Shares are held directly by a trust for the benefit of the Reporting Person's son. |
| Common StockSEC Table I · non-derivative | IndirectBy Children's Trust | 133,215 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 133,215 F3: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
F2: Shares are held directly by a trust for the benefit of the Reporting Person's son.
F3: Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2021 Filed Jun 23, 2021 20:56 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 1,063 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-042764 · doc4.xml · derivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,752 Underlying: Common Stock · 1,063 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 20:56 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,063 | $22.05 | $23,439.15 |
DisclosureSEC source: 0001209191-21-042764 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,254 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $22.00 to $22.115. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 20:56 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 1,063 | $1.79 | $1,902.77 |
DisclosureSEC source: 0001209191-21-042764 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 581,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 23:00 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 8,093 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-038756 · doc4.xml · derivative · entry 7 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,815 Underlying: Common Stock · 8,093 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 23:00 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 8,093 | $22.14 | $179,179.02 |
DisclosureSEC source: 0001209191-21-038756 · doc4.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,254 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $22.00 to $22.34. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 23:00 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 8,093 | $1.79 | $14,486.47 |
DisclosureSEC source: 0001209191-21-038756 · doc4.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 23:00 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 7,005 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-038756 · doc4.xml · derivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,908 Underlying: Common Stock · 7,005 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 23:00 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 7,005 | $22.11 | $154,880.55 |
DisclosureSEC source: 0001209191-21-038756 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,254 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $22.00 to $22.21. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 23:00 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 7,005 | $1.79 | $12,538.95 |
DisclosureSEC source: 0001209191-21-038756 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2021 Filed May 29, 2021 00:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 2,656 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-036710 · doc4.xml · derivative · entry 7 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 433,913 Underlying: Common Stock · 2,656 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| May 28, 2021 Filed May 29, 2021 00:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,656 | $22.16 | $58,856.96 |
DisclosureSEC source: 0001209191-21-036710 · doc4.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,254 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $22.00 to $22.405. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 28, 2021 Filed May 29, 2021 00:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 2,656 | $1.79 | $4,754.24 |
DisclosureSEC source: 0001209191-21-036710 · doc4.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 582,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 27, 2021 Filed May 29, 2021 00:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 12,246 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-036710 · doc4.xml · derivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,569 Underlying: Common Stock · 12,246 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| May 27, 2021 Filed May 29, 2021 00:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 12,246 | $22.10 | $270,636.60 |
DisclosureSEC source: 0001209191-21-036710 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,254 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $22.00 to $22.29. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 27, 2021 Filed May 29, 2021 00:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 12,246 | $1.79 | $21,920.34 |
DisclosureSEC source: 0001209191-21-036710 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 592,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,563 shares acquired under the Employee Stock Purchase Plan on May 17, 2021. Read SEC document |
| April 01, 2021 Filed Apr 7, 2021 00:01 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 310,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001209191-21-025758 · doc4.xml · derivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,000 Underlying: Common Stock · 310,000 shares Expires 2031-03-31 F1 · derivative.exercise_date: 1/48 of shares subject to the option vest on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| March 19, 2021 Filed Mar 24, 2021 00:49 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-022757 · doc4.xml · derivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 448,815 Underlying: Common Stock · 15,000 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 4, 2018, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| March 19, 2021 Filed Mar 24, 2021 00:49 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 15,000 | $25.77 | $386,550.00 |
DisclosureSEC source: 0001209191-21-022757 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 578,691 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.26 to $26.13. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 19, 2021 Filed Mar 24, 2021 00:49 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 15,000 | $1.79 | $26,850.00 |
DisclosureSEC source: 0001209191-21-022757 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 21:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-013782 · doc4.xml · derivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 463,815 Underlying: Common Stock · 15,000 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 4, 2018, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 21:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 6,636 | $26.72 | $177,313.92 |
DisclosureSEC source: 0001209191-21-013782 · doc4.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 578,691 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $26.61 to $26.97. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 21:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 8,364 | $26.27 | $219,722.28 |
DisclosureSEC source: 0001209191-21-013782 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 585,327 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.605 to $26.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 21:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 15,000 | $1.79 | $26,850.00 |
DisclosureSEC source: 0001209191-21-013782 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 23:58 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-004743 · doc4.xml · derivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 478,815 Underlying: Common Stock · 15,000 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 4, 2018, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 23:58 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,567 | $25.87 | $40,538.29 |
DisclosureSEC source: 0001209191-21-004743 · doc4.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 578,691 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.71 to $26.02. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 23:58 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 13,433 | $25.01 | $335,959.33 |
DisclosureSEC source: 0001209191-21-004743 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,258 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $24.66 to $25.655. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 23:58 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 15,000 | $1.79 | $26,850.00 |
DisclosureSEC source: 0001209191-21-004743 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2020 Filed Dec 29, 2020 23:01 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 5,500 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-20-065399 · doc4.xml · derivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 493,815 Underlying: Common Stock · 5,500 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 4, 2018, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 28, 2020 Filed Dec 29, 2020 23:01 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 5,500 | $1.79 | $9,845.00 |
DisclosureSEC source: 0001209191-20-065399 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 578,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 01:44 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-20-064945 · doc4.xml · derivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 499,315 Underlying: Common Stock · 15,000 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 4, 2018, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 01:44 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,113 | $29.88 | $63,136.44 |
DisclosureSEC source: 0001209191-20-064945 · doc4.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 573,191 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $29.73 to $30.165. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 01:44 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 5,691 | $29.08 | $165,494.28 |
DisclosureSEC source: 0001209191-20-064945 · doc4.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575,304 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $28.73 to $29.64. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 01:44 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 7,196 | $28.42 | $204,510.32 |
DisclosureSEC source: 0001209191-20-064945 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,995 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $27.73 to $28.70. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 01:44 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 15,000 | $1.79 | $26,850.00 |
DisclosureSEC source: 0001209191-20-064945 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,562 shares acquired under the Employment Stock Purchase Plan on November 17, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.